A recent phase IIb randomized trial, published in the Journal of Hepatology, evaluated Icosabutate, an oral FFAR1/FFAR4 agonist, in patients with biopsy-confirmed MASH and fibrosis (F1-F3). While the primary endpoint MASH resolution without fibrosis worsening—was not met, the study revealed promising improvements in fibrosis and biomarkers of liver injury and inflammation.
Key findings include:
A higher proportion of patients treated with Icosabutate (300 mg and 600 mg) experienced at least a one-stage fibrosis improvement.
AI-assisted digital pathology confirmed fibrosis improvements.
Significant reductions in markers of liver injury and inflammation, alongside better glycemic control.
A favorable safety profile, with mild to moderate treatment-emergent adverse events (TEAEs) and no drug-induced liver injury.
Despite not meeting the primary endpoint, these findings support further investigation of Icosabutate in MASH patients, especially those with more advanced fibrosis (F2-F3) and type 2 diabetes.
Thanks to the experts behind this important study for their contributions to advancing MASH research.
For more details, read the full study: https://lnkd.in/eighjiXf
